Valeant Pharmaceuticals has announced two acquisitions in as many days, but is being a little coy as to how much it has spent.
Valeant acquired 19.9% in Brazilian biotech firm Pele Nova Biotecnologia for "less than $10 million", it said. It also intends to buy certain assets from Gerot Lannach, a branded generics company based in Austria, for "less than three times sales"
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
